Nov 6 (Reuters) - Bristol Myers Squibb (BMY.N) has acquired Orum Therapeutics’ experimental therapy to treat a type of blood cancer for a total value of up to $180 million, the privately held company said on Monday.
The therapy, ORM-6151, which helps degrade a specific protein hard to treat previously, has received the U.S. Food and Drug Administration’s (FDA) clearance for an early stage study.
The deal includes an upfront payment of $100 million and milestone payments, Orum said, without disclosing further details.

百時美施貴寶

路透 11 月 6 日電 - 私人持股的百時美施貴寶週一表示，該公司已收購 Orum Treateutics 治療一種血癌的實驗性療法，總價值高達 1.8 億美元。

百時美施貴寶以高達 1.8 億美元收購 Orum 的血癌療法